Therapeutic Effects of Adalimumab in Patients with Resistant Psoriasis
Phase 3
- Conditions
- Psoriasis.Psoriasis
- Registration Number
- IRCT20120524009844N8
- Lead Sponsor
- Tabriz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Confirmed pseuriasis
Accepted
Patients without responce to previous treatments
Don’t use of other drugs and herbal supplments
Resistance to atleast one systemic treatment
Exclusion Criteria
Allergy to Adalimumab
Having active inflammation such as tuberculosis, malignancies and etc
Neurological disorders
Hematological disorders
Moderate to severe heart failure
Pregnant and breast feeding woman
Mental retared patients
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Disease severity. Timepoint: At the beginning of the study, 1, 2, 3 and 4 months after receiving the intervention. Method of measurement: Psoriasis Area Severity Index Score.;Quality of life. Timepoint: Initiation of the study, 4 months after receiving the intervention. Method of measurement: Dermatologic Quality of Life Index.
- Secondary Outcome Measures
Name Time Method